Abstract
Purpose :
To report the epidemiology of intraocular inflammation patients at a tertiary center in western Tokyo, Nippon Medical School Tama Nagayama Hospital (NMS-TN) during the recent 5 years, and its comparison with the national multicenter study.
Methods :
We retrospectively reviewed the medical records of 621 patients with intraocular inflammation who presented to the Ocular Inflammation Service at NMS-TN from April 2018.
Results :
The age averaged 55.7±19.5 years. There were 248 males (40.0%) and 373 females (60.0%). The most frequent disease was scleritis in 148 cases (23.8%), followed by sarcoidosis in 60 cases (9.6%), Vogt-Koyanagi-Harada disease in 33 cases (5.3%), herpetic uveitis in 29 cases (4.6%), Behcet's disease in 23 cases (3.7%), acute anterior uveitis in 21 cases (3.3%), and 31.8% were unclassifiable. Secondary glaucoma occurred in 238 patients (38.3%), of which 52 (21.8%) had steroid glaucoma. Biologics were used in 43 patients (6.9%), of which 28 (65.1%) were treated with adalimumab. Scleritis was the most common disease for which biologics were used in 16 cases (37.2%), followed by Behcet's disease in 14 cases (32.5%), and sarcoidosis, TINU, and unclassifiable uveitis in the others. The top 6 most frequent diseases were consistent with the national multicenter ocular inflammatory disease statistics (JJO 2021), but the present study differed in a way that scleritis was the most common disease because the patients with scleritis are referred to NMS-TN not only from Tokyo but also across the country. Compared to our previous report (JJO 2015), scleritis increased from 17.0% to 23.8%, and the incidence of secondary glaucoma was also higher in our study. There was also an increased frequency of cytomegalovirus corneal endothelitis or iridocyclitis, and intraocular lymphoma, because of advances in techniques for examination and diagnostic of intraocular fluid.
Conclusions :
Scleritis was remarkably common at the Ocular Inflammation Service in NMS-TN as it was referred from all over the country, and the incidence of secondary glaucoma was about 40%. Overall, the use of biologics was about 7%.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.